Pharmaceutical

AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment

AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.

Dec 25, 2024 - 06:00
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment
AstraZeneca has gained approval from the European Commission for its oral therapy, Tagrisso (osimertinib), to treat adults with NSCLC.
Read the original article

Tags:

Previous Article

RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement

Next Article

FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Proposed rules to protect health data in an era of abortion bans fall short

Opinion: Proposed rules to protect health data in an er...

May 13, 2023

12,000 diseases lack treatments. One doctor thinks generics could yield cures

12,000 diseases lack treatments. One doctor thinks gene...

May 5, 2023

Twist Bioscience and Astellas team up for antibody discovery

Twist Bioscience and Astellas team up for antibody disc...

Apr 22, 2023